Damaj Ghandi, Kuhnowski Frédérique, Marolleau Jean-Pierre, Bauters Francis, Leleu Xavier, Yakoub-Agha Ibrahim
Hematology, Amiens University Medical Center, Amiens, France.
Eur J Haematol. 2009 Sep;83(3):246-50. doi: 10.1111/j.1600-0609.2009.01259.x. Epub 2009 Mar 19.
Although the survival of patients with hairy cell leukemia (HCL) has been improved by the therapeutic introduction of interferon alpha and purine analogs, it is still worsened by complications such as severe infections. In this long-term study, we identified factors influencing patient outcomes in 73 patients with HCL. Median age at diagnosis was 53 yr and the gender ratio (M/F) was 2.3. At the time of HCL diagnosis, 60 patients (82%) were symptomatic and 22 of these had an infection. After a median follow-up of 13 yr, eight patients had died of secondary cancer (n = 2), HCL progression (n = 1) and age-related complications (n = 5). The 10-yr overall survival (OS), progression-free survival and relapse rates were 91 +/- 3%, 14 +/- 5% and 87 +/- 5%, respectively. In multivariate analyses, age >53 yr was the only factor adversely influencing OS and secondary cancer incidence, with adjusted hazard ratio (HR) of 9.30 (95%CI, 1.15-76.6; P = 0.037) and 2.80 (95%CI, 1.05-7.71; P = 0.04), respectively. Eleven patients developed severe infections. Absolute lymphocyte count (<1 x 10(9)/L) at diagnosis was the only factor influencing the occurrence of severe infections, with an adjusted HR of 4.01 (P = 0.007). Strikingly, we did not observe any significant correlation between neutrophil or monocyte counts and the incidence of infection. We confirmed long-term survival in HCL but found a high incidence of infection - even late in the course of the disease. The absolute lymphocyte count at diagnosis is a risk factor for the occurrence of severe infections. In addition to careful monitoring of infections, prompt initiation of anti-HCL treatment should be considered in patients with low lymphocyte counts.
尽管通过引入干扰素α和嘌呤类似物进行治疗,毛细胞白血病(HCL)患者的生存率有所提高,但仍会因严重感染等并发症而恶化。在这项长期研究中,我们确定了影响73例HCL患者预后的因素。诊断时的中位年龄为53岁,性别比(男/女)为2.3。在HCL诊断时,60例患者(82%)有症状,其中22例有感染。中位随访13年后,8例患者死于继发性癌症(n = 2)、HCL进展(n = 1)和与年龄相关的并发症(n = 5)。10年总生存率(OS)、无进展生存率和复发率分别为91±3%、14±5%和87±5%。在多变量分析中,年龄>53岁是唯一对OS和继发性癌症发生率有不利影响的因素,调整后的危险比(HR)分别为9.30(95%CI,1.15 - 76.6;P = 0.037)和2.80(95%CI,1.05 - 7.71;P = 0.04)。11例患者发生严重感染。诊断时的绝对淋巴细胞计数(<1×10⁹/L)是影响严重感染发生的唯一因素,调整后的HR为4.01(P = 0.007)。令人惊讶的是,我们未观察到中性粒细胞或单核细胞计数与感染发生率之间存在任何显著相关性。我们证实了HCL患者的长期生存,但发现感染发生率很高——即使在疾病后期也是如此。诊断时的绝对淋巴细胞计数是发生严重感染的危险因素。除了仔细监测感染外,对于淋巴细胞计数低的患者,应考虑及时开始抗HCL治疗。